Postmenopausal estrogen replacement therapy and risk of AD

A population-based study

S. C. Waring, Walter A Rocca, Ronald Carl Petersen, P. C. O'Brien, Eric George Tangalos, E. Kokmen

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

Objective: To study the association between estrogen replacement therapy in postmenopausal women and AD using a case-control design. Background: Studies of the effect of estrogen therapy on the risk of AD have been limited and have yielded conflicting results. Methods: Case patients were all postmenopausal women who developed AD in the quinquennium 1980 through 1984 in Rochester, MN (n = 222). One control subject from the same population and free of dementia was matched to each case patient by age (±3 years) and length of enrollment in the records-linkage system (n = 222). Estrogen exposure was defined as any form of estrogen (oral, parenteral, topical, suppository) used for at least 6 months after the onset of menopause and before the onset of AD (or corresponding year in the matched control subject). Information on dose and duration of use was abstracted. Consistent with the matched design, analyses entailed conditional logistic regression. Results: AD patients and control subjects had identical age at menarche (median: 13.0 versus 13.0 years) and age at menopause (median: 50.0 versus 50.0 years). The frequency of estrogen use was higher among control subjects than AD patients (10% versus 5%; odds ratio = 0.42; 95% confidence interval 0.18 to 0.96; p = 0.04). There was a significant trend of decreasing odds ratios with increasing duration of use. The inverse association between estrogen therapy and AD remained significant after adjustment for education and age at menopause. Conclusion: These results from a population-based study suggest that estrogen replacement therapy is associated with a reduced risk of AD in postmenopausal women.

Original languageEnglish (US)
Pages (from-to)965-970
Number of pages6
JournalNeurology
Volume52
Issue number5
StatePublished - Mar 23 1999

Fingerprint

Estrogen Replacement Therapy
Estrogens
Menopause
Population
Odds Ratio
Suppositories
Menarche
Dementia
Logistic Models
Confidence Intervals
Education
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Postmenopausal estrogen replacement therapy and risk of AD : A population-based study. / Waring, S. C.; Rocca, Walter A; Petersen, Ronald Carl; O'Brien, P. C.; Tangalos, Eric George; Kokmen, E.

In: Neurology, Vol. 52, No. 5, 23.03.1999, p. 965-970.

Research output: Contribution to journalArticle

@article{e63001ac6a8a45ec97343ea5b487b5e1,
title = "Postmenopausal estrogen replacement therapy and risk of AD: A population-based study",
abstract = "Objective: To study the association between estrogen replacement therapy in postmenopausal women and AD using a case-control design. Background: Studies of the effect of estrogen therapy on the risk of AD have been limited and have yielded conflicting results. Methods: Case patients were all postmenopausal women who developed AD in the quinquennium 1980 through 1984 in Rochester, MN (n = 222). One control subject from the same population and free of dementia was matched to each case patient by age (±3 years) and length of enrollment in the records-linkage system (n = 222). Estrogen exposure was defined as any form of estrogen (oral, parenteral, topical, suppository) used for at least 6 months after the onset of menopause and before the onset of AD (or corresponding year in the matched control subject). Information on dose and duration of use was abstracted. Consistent with the matched design, analyses entailed conditional logistic regression. Results: AD patients and control subjects had identical age at menarche (median: 13.0 versus 13.0 years) and age at menopause (median: 50.0 versus 50.0 years). The frequency of estrogen use was higher among control subjects than AD patients (10{\%} versus 5{\%}; odds ratio = 0.42; 95{\%} confidence interval 0.18 to 0.96; p = 0.04). There was a significant trend of decreasing odds ratios with increasing duration of use. The inverse association between estrogen therapy and AD remained significant after adjustment for education and age at menopause. Conclusion: These results from a population-based study suggest that estrogen replacement therapy is associated with a reduced risk of AD in postmenopausal women.",
author = "Waring, {S. C.} and Rocca, {Walter A} and Petersen, {Ronald Carl} and O'Brien, {P. C.} and Tangalos, {Eric George} and E. Kokmen",
year = "1999",
month = "3",
day = "23",
language = "English (US)",
volume = "52",
pages = "965--970",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Postmenopausal estrogen replacement therapy and risk of AD

T2 - A population-based study

AU - Waring, S. C.

AU - Rocca, Walter A

AU - Petersen, Ronald Carl

AU - O'Brien, P. C.

AU - Tangalos, Eric George

AU - Kokmen, E.

PY - 1999/3/23

Y1 - 1999/3/23

N2 - Objective: To study the association between estrogen replacement therapy in postmenopausal women and AD using a case-control design. Background: Studies of the effect of estrogen therapy on the risk of AD have been limited and have yielded conflicting results. Methods: Case patients were all postmenopausal women who developed AD in the quinquennium 1980 through 1984 in Rochester, MN (n = 222). One control subject from the same population and free of dementia was matched to each case patient by age (±3 years) and length of enrollment in the records-linkage system (n = 222). Estrogen exposure was defined as any form of estrogen (oral, parenteral, topical, suppository) used for at least 6 months after the onset of menopause and before the onset of AD (or corresponding year in the matched control subject). Information on dose and duration of use was abstracted. Consistent with the matched design, analyses entailed conditional logistic regression. Results: AD patients and control subjects had identical age at menarche (median: 13.0 versus 13.0 years) and age at menopause (median: 50.0 versus 50.0 years). The frequency of estrogen use was higher among control subjects than AD patients (10% versus 5%; odds ratio = 0.42; 95% confidence interval 0.18 to 0.96; p = 0.04). There was a significant trend of decreasing odds ratios with increasing duration of use. The inverse association between estrogen therapy and AD remained significant after adjustment for education and age at menopause. Conclusion: These results from a population-based study suggest that estrogen replacement therapy is associated with a reduced risk of AD in postmenopausal women.

AB - Objective: To study the association between estrogen replacement therapy in postmenopausal women and AD using a case-control design. Background: Studies of the effect of estrogen therapy on the risk of AD have been limited and have yielded conflicting results. Methods: Case patients were all postmenopausal women who developed AD in the quinquennium 1980 through 1984 in Rochester, MN (n = 222). One control subject from the same population and free of dementia was matched to each case patient by age (±3 years) and length of enrollment in the records-linkage system (n = 222). Estrogen exposure was defined as any form of estrogen (oral, parenteral, topical, suppository) used for at least 6 months after the onset of menopause and before the onset of AD (or corresponding year in the matched control subject). Information on dose and duration of use was abstracted. Consistent with the matched design, analyses entailed conditional logistic regression. Results: AD patients and control subjects had identical age at menarche (median: 13.0 versus 13.0 years) and age at menopause (median: 50.0 versus 50.0 years). The frequency of estrogen use was higher among control subjects than AD patients (10% versus 5%; odds ratio = 0.42; 95% confidence interval 0.18 to 0.96; p = 0.04). There was a significant trend of decreasing odds ratios with increasing duration of use. The inverse association between estrogen therapy and AD remained significant after adjustment for education and age at menopause. Conclusion: These results from a population-based study suggest that estrogen replacement therapy is associated with a reduced risk of AD in postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=0033596811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033596811&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 965

EP - 970

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -